Catalog No.
Product Name
Application
Product Information
Citations
-
HDAC3 Inhibitor
(E,E)-RGFP966 is a selective inhibitor of Histone Deacetylase 3 (HDAC3) that is capable of penetrating the central nervous system. This compound is particularly relevant for the investigation of neurodegenerative disorders, including Huntington's disease. Its specificity for HDAC3 makes it a valuable tool in studying the epigenetic regulation of gene expression and the accompanying mechanistic pathways involved in this condition. -
DNMT And HDAC Aual Inhibitor
DNMT/HDAC-IN-1 is a dual inhibitor targeting DNA methyltransferases (DNMT) and histone deacetylases (HDACs), demonstrating IC50 values of 56.84 nM for HDAC1 and 17.39 nM for HDAC6. This compound induces apoptosis in tumor cells and is valuable for cancer research applications, providing insights into the mechanisms of epigenetic regulation in malignancies. Its role in modulating both DNMT and HDAC activities makes it a significant tool for investigating therapeutic strategies in oncology. -
HDAC1 Inhibitor
HDAC1-IN-7 is a potent inhibitor of histone deacetylase 1 (HDAC1), exhibiting an IC50 of 0.957 mM. This compound serves as a valuable tool for investigating the role of HDAC1 in various biological processes, including gene expression regulation and cellular differentiation. Its application is relevant in studies of cancer biology and neurodegenerative disorders, where modulation of HDAC1 activity may provide insights into therapeutic strategies. -
HDAC11 Inhibitor
HDAC11-IN-2 is a selective inhibitor of Histone Deacetylase 11 (HDAC11), exhibiting an IC50 of 51.1 µM for HDAC11 and 5 µM for HDAC8. This compound effectively inhibits de novo lipogenesis and promotes fatty acid oxidation, addressing hepatic lipid accumulation and its associated pathological features in MASLD mouse models. Additionally, HDAC11-IN-2 enhances the phosphorylation of AMPKα1 at Thr172, further regulating metabolic pathways involved in lipid metabolism within the liver. -
HDAC6 Inhibitor
Bavarostat is a potent inhibitor of histone deacetylase 6 (HDAC6) with an IC50 of 17 nM, capable of crossing the blood-brain barrier. As a PET radiotracer, it can be labeled with 18F for in vivo mapping of HDAC6 distribution and assessing target occupancy in non-human primate models. Bavarostat selectively enhances tubulin acetylation without affecting histone acetylation, making it a valuable tool for research into neurodegenerative diseases, such as Alzheimer’s, as well as various cancers. -
PROTAC HDAC6 Degrader
HDAC6 Degrader-3 is a selective inhibitor that promotes the degradation of histone deacetylase 6 (HDAC6) through ternary complex formation and the ubiquitin-proteasome pathway, exhibiting a DC50 value of 19.4 nM. With IC50 values of 4.54 nM for HDAC6 and 0.647 μM for HDAC1, it effectively induces significant hyperacetylation of α-tubulin. This compound is valuable for research applications focused on neurodegenerative diseases and cancer, where modulation of HDAC6 activity may play a critical role. -
PROTAC HDAC Degrader
HD-TAC7 is a highly effective PROTAC HDAC degrader, specifically targeting histone deacetylases HDAC1, HDAC2, and HDAC3 with IC50 values of 3.6 μM, 4.2 μM, and 1.1 μM, respectively. This compound has demonstrated the ability to reduce NF-κB p65 levels in RAW 264.7 macrophages. HD-TAC7 is suitable for research applications focused on inflammatory diseases, including asthma and chronic obstructive pulmonary disease (COPD). -
HDAC11 Inhibitor
TD034 is a selective, reversible, and noncovalent inhibitor of HDAC11, exhibiting an IC50 value of 5.1 nM and a Ki of 1.5 nM. This compound specifically targets HDAC11 without affecting other histone deacetylases or sirtuins, and it inhibits the defatty acylation of the substrate SHMT2. Additionally, TD034 reduces the levels of YAP1 through its action on HDAC11. This reagent is suitable for investigating the role of HDAC11 in lung cancer research. -
HDAC6/MAO-A/LSD1 Inhibitor
HDAC6-IN-3 is a potent inhibitor of histone deacetylase 6 (HDAC6), with an IC50 ranging from 0.02 to 1.54 μM for various HDAC isoforms, including HDAC1, HDAC2, HDAC3, and HDAC8. Additionally, it exhibits significant inhibitory activity against monoamine oxidase A (MAO-A) with an IC50 of 0.79 μM and lysine-specific demethylase 1 (LSD1). This compound serves as a valuable tool for research applications in cancer biology and epigenetics and is equipped with an alkyne functionality, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc). -
HDAC6 Inhibitor
HDAC6-IN-23 is a potent inhibitor of the histone deacetylase HDAC6, exhibiting oral bioavailability. This compound demonstrates significant biological activity by modulating histone acetylation, which plays a crucial role in gene regulation and cellular processes. It is primarily utilized in research focused on neurodegenerative disorders, cancer therapy, and the study of protein homeostasis. -
HDAC Ligand
HDAC Ligand-1 is a selective histone deacetylase (HDAC) ligand that serves as a valuable building block for the synthesis of PROTAC HDAC degraders. This compound can facilitate the development of innovative therapeutic agents targeting HDAC enzymes, enhancing the understanding of their role in various biological processes. Its applications extend to cancer research and epigenetic studies, providing insights into the modulation of gene expression and cellular behavior. -
HDAC6/10 Inhibitor
HDAC-IN-4 is a selective inhibitor of HDAC6 and HDAC10, demonstrating pIC50 values of 7.2 and 6.8 in BRET assays, respectively. This compound exhibits antitumoral activity, making it a significant tool for the investigation of cancer biology and the modulation of gene expression. Its selective inhibition of these histone deacetylases positions HDAC-IN-4 as a valuable reagent for research focusing on epigenetic regulation and potential therapeutic applications in cancer treatment. -
HDAC Inhibitor
BG48 is a potent histone deacetylase (HDAC) inhibitor that selectively targets HDAC1 and HDAC2. By inhibiting the enzymatic activity of these enzymes, BG48 modulates gene expression and can influence cellular processes such as differentiation, proliferation, and apoptosis. This compound is valuable for research applications in cancer biology, neurodegenerative diseases, and epigenetic studies. -
HDAC I/IIb Inhibitor
Purinostat is a selective inhibitor of histone deacetylases (HDAC) I and IIb, exhibiting potent anti-leukemic activity. It effectively reduces the survival of Philadelphia chromosome-positive leukemic cells and CD34+ leukemic progenitors from chronic myeloid leukemia patients. By targeting HDAC I/IIb, Purinostat disrupts critical pathways for leukemic stem cell survival, influencing factors such as c-Myc, β-Catenin, E2F, Ezh2, Alox5, and mTOR. Additionally, Purinostat enhances glutamate metabolism in leukemic stem cells by upregulating GLS1. -
HDAC Inhibitor
HNHA is a potent histone deacetylase (HDAC) inhibitor with an IC50 of 100 nM. The compound effectively induces cell cycle arrest at the G1/S phase through the upregulation of p21. HNHA has demonstrated the ability to inhibit tumor growth and neovascularization, suggesting potential applications in cancer research, particularly in the context of breast cancer therapeutics. -
PROTAC HDAC Degrader
JPS036 is a benzamide-based HDAC degrader that operates through the Von Hippel-Lindau (VHL) E3-ligase proteolysis targeting chimera (PROTAC) mechanism. This compound selectively degrades class I histone deacetylases (HDAC1 and HDAC2), demonstrating significant biological activity by promoting the expression of differentially expressed genes and enhancing apoptosis in HCT116 cells. JPS036 serves as a valuable research tool for studying the roles of HDACs in cellular processes and disease models. -
HDAC Inhibitor
HDAC-IN-40 is a potent alkoxyamide-based inhibitor of histone deacetylases (HDACs), specifically targeting HDAC2 and HDAC6 with Ki values of 60 nM and 30 nM, respectively. This compound exhibits significant antitumor activity, making it a valuable tool for cancer research. HDAC-IN-40 can be utilized to explore the role of histone deacetylation in tumor development and progression, as well as to investigate potential therapeutic interventions in various cancers. -
HDAC1/2 Inhibitor
BG47 is a selective inhibitor of histone deacetylases HDAC1 and HDAC2, functioning as an optoepigenetic probe. Upon light-induced trans-to-cis isomerization, BG47 competitively inhibits the deacetylase activity of its targets, resulting in increased acetylation of Histone H3K9. This compound is relevant for research applications in neurological diseases, providing insights into epigenetic regulation and its implications in various disorders. -
HDAC6 Inhibirotr
HDAC6-IN-65 is a selective inhibitor of histone deacetylase 6 (HDAC6) with an IC50 of 0.9 nM, demonstrating additional inhibitory effects on HDAC3 with an IC50 of 39.4 nM. This compound induces the accumulation of acetylated α-tubulin and acetylated histone H3 in Neuro-2a cells, serving as a marker for class I HDAC inhibition. HDAC6-IN-65 provides valuable insights in the study of melanoma and related cancer research applications. -
Anti-inflammatory Agent
NPB-1575 is a potent, orally bioavailable anti-inflammatory agent that effectively targets neuroinflammation. It functions by activating the IRS2/Nrf2/NF-κB signaling axis, thereby combating ferroptosis and providing neuroprotection. NPB-1575 demonstrates efficacy in mitigating cerebral ischemic injury and enhancing neurological outcomes, making it a valuable tool for research focused on ischemic stroke and related neurodegenerative conditions. -
Ferroptosis Inhibitor
5-Hydroxy-6,7-dimethoxyflavone is a potent inhibitor of ferroptosis, acting primarily to mitigate H1N1 virus-induced cell death. This compound enhances the expression of SLC7A11 and GPX4, thereby providing protective effects against ferroptosis. Additionally, it reduces inflammatory responses and apoptosis by inhibiting the activation of NF-κB and p38 MAPK signaling pathways. 5-Hydroxy-6,7-dimethoxyflavone is valuable for research related to H1N1 influenza virus infection and ferroptosis regulation. -
HDAC Inhibitor
HDAC-IN-48 is a potent inhibitor of histone deacetylases (HDACs) that exhibits significant cytotoxicity, with a GI50 of approximately 20 nM. This hybrid molecule incorporates pharmacophores from SAHA and CETZOLE, effectively inducing ferroptosis while inhibiting HDAC activity. Additionally, HDAC-IN-48 features an alkyne group, allowing it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc) reactions, making it a valuable tool for click chemistry applications in chemical biology and therapeutic research. -
Stable Isotope
(±)-Epicatechin-13C3 is a stable isotope-labeled form of (±)-Epicatechin, which primarily interacts with cyclooxygenase-1 (COX-1). This compound exhibits significant inhibition of COX-1 activity, with an IC50 value of 3.2 μM. Additionally, (±)-Epicatechin is known to suppress the IL-1β-induced expression of inducible nitric oxide synthase (iNOS) by preventing the nuclear translocation of the p65 subunit of NF-κB. These properties make (±)-Epicatechin-13C3 valuable for studies focused on inflammation and signal transduction pathways. -
HDAC11 Inhibitor
HDAC11-IN-3 is a selective inhibitor of HDAC11, exhibiting an IC50 of 4.1 nM. This compound demonstrates potent anti-acute myeloid leukemia (AML) activity against U937 and OCI-AML2 cell lines with an IC50 of 10 μM. It effectively induces apoptosis, cell cycle arrest, and differentiation while upregulating iron transporters transferrin (TF) and transferrin receptor (TFRC). Additionally, HDAC11-IN-3 activates the p62-Keap1-Nrf2-HMOX1 pathway, resulting in elevated intracellular iron levels and subsequent ferroptosis in AML cells. This reagent is suited for studies investigating the molecular mechanisms of AML and can be utilized alone or in combination with other therapeutic agents like Cytarabine. -
Stable Isotope
Sulfasalazine-d4 is a deuterium-labeled derivative of the anti-rheumatic agent Sulfasalazine, primarily used in the investigation of rheumatoid arthritis and ulcerative colitis. This compound is known to inhibit NF-κB activity and serves as a type 1 ferroptosis inducer. Its stable isotope labeling enhances analytical techniques, aiding in the study of pharmacokinetics and metabolic pathways associated with Sulfasalazine's biological effects. -
Bacterial Inhibitor; IKKβ Inhibitor
Abietic acid is a diterpene compound that acts as an IKKβ inhibitor, showcasing significant antibacterial properties alongside anti-inflammatory and anti-proliferative effects. It exhibits remarkable activity in ameliorating liver injury, enhancing cell migration, and promoting angiogenesis through ERK and p38 upregulation. Abietic acid has demonstrated efficacy in reducing non-small-cell lung cancer (NSCLC) cell proliferation and shows potential for addressing conditions such as psoriasis and sepsis-induced lung injury by modulating inflammatory pathways. Its diverse biological activities make it a valuable reagent for research in cancer, liver diseases, and inflammatory disorders. -
Apoptosis/Autophagy Inducer
Formosanin C is a diosgenin saponin that functions primarily as an apoptosis and autophagy inducer. It exhibits notable anti-tumor activities through mechanisms such as blocking the cell cycle, inhibiting metastasis, and promoting ferroptosis. Additionally, Formosanin C can suppress the NF-κB signaling pathway, providing anti-inflammatory effects while enhancing immune cell activity. This compound is relevant for research in anti-inflammatory, antifungal, and anti-cancer applications, particularly concerning lung, liver, breast, and colorectal cancers. -
Na+ Channel Blocker
Lidocaine hydrochloride hydrate is a sodium channel blocker that selectively inhibits voltage-gated sodium channels, demonstrating use dependence. It has been shown to reduce growth, migration, and invasion of gastric carcinoma cells by up-regulating miR-145 expression, which subsequently leads to the inactivation of the MEK/ERK and NF-κB signaling pathways. Additionally, as an amide derivative, lidocaine hydrochloride hydrate has potential applications in the study of ventricular arrhythmias. -
P2X7 Antagonist
Bullatine A is a potent P2X7 antagonist with significant anti-inflammatory and anti-nociceptive properties. It effectively inhibits ATP-induced BV-2 cell apoptosis and modulates inflammatory responses mediated by P2X receptors. Bullatine A has demonstrated the ability to reduce glioma cell growth by targeting SIRT6, alleviate pain hypersensitivity in rodent models, and mitigate systemic inflammation via the ROS/JNK/NF-κB pathway. Additionally, it has shown potential in improving behavioral outcomes in models of chronic social defeat stress. This compound is valuable for research in inflammation, glioblastoma, and depression. -
NF-κB Inhibitor
Ginsenoside Rg6 is an NF-κB inhibitor that effectively attenuates TNF-α-induced NF-κB transcriptional activity, exhibiting an IC50 of 29.34 μM in HepG2 cells. In addition to its role in modulating NF-κB activity, Ginsenoside Rg6 demonstrates significant apoptotic effects, making it a valuable tool for research in inflammation and cancer biology. -
Antipsychotic Agent
Penfluridol is a potent, long-acting antipsychotic agent that primarily targets D2-like dopamine receptors. It exhibits significant anti-inflammatory properties by inhibiting TNFα-induced NF-κB activation and demonstrates efficacy in models of arthritis and colitis. Additionally, Penfluridol acts as a Ca2+-calmodulin inhibitor, inducing apoptosis and autophagy in various cellular contexts. This compound is utilized in research focusing on chronic schizophrenia, acute psychosis, Tourette syndrome, autoimmune diseases, and it also shows antibacterial activity against E. faecalis with a minimum inhibitory concentration of 7.81 μg/ml. -
Pharmaceutical Excipient
Sodium benzoate functions as a pharmaceutical excipient with multiple roles, including serving as an antibacterial agent and preservative. It enhances the stability, solubility, and processability of drug formulations while potentially influencing the absorption, distribution, metabolism, and elimination (ADME) of co-administered compounds. Additionally, sodium benzoate activates the NF-κB signaling pathway, induces apoptosis, and has been studied for its immunosuppressive effects as well as reproductive toxicity. Its applications extend to research in colon cancer and immune diseases. -
Antibiotic
Lambertellin is an antibiotic with bactericidal and fungicidal properties. It demonstrates significant anti-inflammatory activity in LPS-stimulated RAW 264.7 macrophage cells by modulating the MAPK and NF-κB signaling pathways. This compound is valuable for research focused on antimicrobial resistance and inflammatory responses. -
Radical Scavenger
Rubiadin is a polyketide-derived compound that acts as a free radical scavenger, effectively inhibiting the activation of the NF-κB signaling pathway. Its biological activities include the inhibition of osteoclast formation, bone resorption, lipid peroxidation, and cancer cell proliferation, along with the reduction of pro-inflammatory cytokine levels and induction of cancer cell apoptosis. Rubiadin demonstrates a diverse range of applications in research related to osteoporosis, inflammatory diseases, viral infections such as hepatitis B, various cancers, and both fungal and bacterial infections. -
Antifungal Agent
Sulconazole is a potent antifungal agent belonging to the imidazole class, primarily known for its ability to inhibit fungal growth. It exerts its effects by blocking the NF-κB/IL-8 signaling pathway, which is implicated in cancer stem cell formation and tumor progression. Additionally, Sulconazole shows potential for applications in breast cancer research, highlighting its dual role as both an antifungal and an anti-tumor compound. -
Anti-Inflammatory Agent
Nepetoidin B is an anti-inflammatory agent that exerts its effects by modulating the NF-κB and Nrf2/HO-1 signaling pathways. In addition to its anti-inflammatory properties, Nepetoidin B also demonstrates antifungal and antibacterial activities. This natural compound, derived from Salvia plebeia R. Br., is suitable for research applications focused on inflammation and infectious diseases. -
Fungal Metabolite
Heveadride is a fungal metabolite that functions as an antifungal agent. It exhibits activity against a range of filamentous fungi as well as certain human pathogenic yeasts. Additionally, Heveadride has been shown to induce down-regulation of TNFα-induced NF-κB activity in human chronic myeloid leukemia cells, with an IC50 of 82.7 μM, making it a valuable tool for research in antifungal treatments and cancer biology. -
CXCR Inhibitor
Corydalmine, a CXCR inhibitor, demonstrates significant antifungal activity by inhibiting spore germination in various plant pathogenic and saprophytic fungi. Additionally, it serves as an oral analgesic agent, exhibiting potent analgesic effects. Corydalmine has been shown to alleviate Vincristine-induced neuropathic pain in murine models through the inhibition of the NF-κB-dependent CXCL1/CXCR2 signaling pathway, making it a valuable tool for pain research and therapeutic applications. -
CYP51/PD-L1 Inhibitor
CYP51/PD-L1-IN-3 is a dual inhibitor targeting CYP51 and PD-L1, exhibiting potent antifungal activity with IC50 values of 0.205 μM and 0.039 μM, respectively. This compound induces early apoptosis in fungal cells by reducing levels of intracellular IL-2, NLRP3, and NF-κBp65 proteins. Additionally, CYP51/PD-L1-IN-3 causes mitochondrial damage and reactive oxygen species (ROS) accumulation, ultimately resulting in fungal lysis and cell death. This compound serves as a valuable tool for research in fungal infections and immune modulation. -
CYP51/PD-L1 Inhibitor
CYP51/PD-L1-IN-2 is a quinazoline compound that functions as a dual inhibitor of CYP51 and PD-L1, exhibiting IC50 values of 0.263 μM and 0.017 μM, respectively. It displays notable antifungal activity by triggering early apoptosis in fungal cells, leading to significant reductions in intracellular IL-2, NLRP3, and NF-κBp65 protein levels. Additionally, CYP51/PD-L1-IN-2 induces mitochondrial damage and reactive oxygen species (ROS) accumulation, culminating in fungal lysis and subsequent cell death. This compound is valuable for research exploring antifungal mechanisms and cancer immunotherapy. -
CYP51/PD-L1 Inhibitor
CYP51/PD-L1-IN-1 is a dual inhibitor targeting both CYP51 and PD-L1, exhibiting an IC50 of 0.884 μM for CYP51 and 0.083 μM for PD-L1. This quinazoline compound demonstrates notable antifungal activity by inducing early apoptosis in fungal cells while significantly reducing intracellular levels of IL-2, NLRP3, and NF-κBp65. Additionally, CYP51/PD-L1-IN-1 contributes to mitochondrial damage and reactive oxygen species (ROS) accumulation, ultimately leading to fungal lysis and cell death. This compound is valuable for research focused on antifungal therapies and immune modulation. -
CXCR Inhibitor
Corydalmine hydrochloride is a potent CXCR inhibitor that demonstrates significant biological activity by inhibiting spore germination in certain plant pathogenic and saprophytic fungi. Additionally, it exhibits notable analgesic properties, effectively alleviating Vincristine-induced neuropathic pain in murine models. This effect is mediated through the inhibition of the NF-κB-dependent CXCL1/CXCR2 signaling pathway, highlighting its potential applications in pain management research and fungal inhibition studies. -
Anti-Diabetic Drug
Gliquidone is an anti-diabetic agent that primarily targets pancreatic β-cells to enhance insulin secretion, thereby helping regulate blood glucose levels. It has demonstrated significant anti-inflammatory effects by reducing LPS-induced proinflammatory responses and inhibiting the phosphorylation of ERK, STAT3, and NF-κB in BV2 microglial cells. Additionally, Gliquidone effectively suppresses microgliosis and microglial hypertrophy while lowering levels of proinflammatory cytokines, such as COX-2 and IL-6, in murine models. Furthermore, Gliquidone exhibits anticancer activity against lung carcinoma cells and possesses antioxidant properties, making it valuable for research in type 2 diabetes and cancer. -
IGF-1R Agonist
Ginsenoside Rg5 is a potent IGF-1R agonist primarily derived from Red ginseng. It functions by competing at the IGF-1 binding site on IGF-1R, effectively obstructing IGF-1's interaction and exhibiting an IC50 of approximately 90 nM. Additionally, Ginsenoside Rg5 downregulates COX-2 mRNA expression through inhibition of NF-κB p65 DNA binding activities, making it valuable for research into inflammation and metabolic regulation. -
Multifunctional Bioactive Compound
Gypenoside XLIX is a multifunctional bioactive compound derived from Gynostemma pentaphyllum, exhibiting a binding affinity (Ka) of 1.58 μM for SIRT1. This compound functions as a PPAR-α agonist and has demonstrated significant anti-inflammatory and antioxidative properties through the activation of the Sirt1/Nrf2 signaling pathway. Gypenoside XLIX effectively inhibits the TLR4-mediated NF-κB signaling pathway, reduces reactive oxygen species accumulation, and ameliorates various conditions including sepsis-induced liver, kidney, and splenic injuries. Its applications extend to studies on acute liver injury, cardiomyopathy, sepsis-associated encephalopathy, and chronic inflammation, making it a valuable tool for research in diverse biological contexts. -
IKKε/TBK-1 Inhibitor
MRT67307 dihydrochloride is a potent inhibitor of IKKε and TBK-1, demonstrating IC50 values of 160 nM and 19 nM, respectively. Additionally, this compound inhibits ULK1 and ULK2 with IC50s of 45 nM and 38 nM, respectively. MRT67307 dihydrochloride plays a significant role in blocking autophagy in cellular environments, making it a valuable tool for studies involving inflammation and autophagic processes. -
IKKε Inhibitor
IKKε-IN-1 is a selective inhibitor of IKKε, a key enzyme involved in the NF-κB signaling pathway. This compound effectively reduces cell viability, inhibits colony formation, and diminishes cell migration in various cancer cell lines. Additionally, IKKε-IN-1 induces autophagy, illustrating its potential as a research tool in the study of multiple cancer types, including colorectal, hepatocellular, bladder, breast, lung, and cervical cancers. -
Anti-inflammatory Agent
Hexadecanamide is a fatty acid amide that serves as an anti-inflammatory agent, exhibiting protective effects against Staphylococcus aureus and SARA-induced mastitis. It functions by suppressing S. aureus-mediated NF-κB activation and enhancing blood-milk barrier integrity. Additionally, Hexadecanamide activates PPARα and has been shown to improve sperm motility in vitro. This compound is relevant for research applications involving mastitis and asthenozoospermia. -
PPARγ Activator
Convallatoxin is a PPARγ activator derived from the plant Adonis amurensis. It exhibits significant anti-inflammatory effects by mitigating colitic inflammation through the activation of PPARγ and the suppression of NF-κB signaling pathways. Additionally, Convallatoxin serves as a substrate for P-glycoprotein, identifying Val982 as a critical amino acid for its transport. This compound also enhances ligand-induced micro-opioid receptor (MOR) endocytosis, demonstrating high potency and efficacy, making it valuable for research in inflammation and cellular signaling. -
PPAR Agonist
4-O-Methyl honokiol is a natural neolignan derived from Magnolia officinalis that functions as a selective PPARγ agonist. It exhibits significant inhibition of NF-κB activity, making it a valuable tool for studying mechanisms of inflammation and cancer. Its biological activity is particularly relevant in research focused on metabolic regulation and inflammatory responses.
